Treatment with the vitamin D analog EB1089 effectively inhibits aromatase-dependent growth of breast cancer cells by dissociating BAZ1B from the CYP19A1 promoter in a vitamin D receptor (VDR)-dependent manner, suggesting that BAZ1B is a potential drug target in breast cancer [70, 71] (Fig. 4C). The gene discussed is CYP19A1; the disease is breast cancer.